Avanir Pharmaceuticals to Present Data on ONZETRA™ Xsail™ at American Headache Society (AHS) 2016 Annual Scientific Meeting

Avanir Pharmaceuticals, Inc. today announced that the company will be presenting results from several studies about ONZETRA™ Xsail™ (sumatriptan nasal powder) 11 mg per nose piece, formerly AVP-825, at the 58th American Headache Society Annual Scientific Meeting being held in San Diego from June 9-12, 2016. ONZETRA Xsail was approved by the U.S. Food and Drug Administration (FDA) in January 2016 and is now available for prescription for the acute treatment of migraine with or without aura in adults. "We are excited to present data about ONZETRA Xsail at this year's AHS Annual Meeting as these results will provide additional information to help healthcare professionals and patients determine the best treatment for migraine, an area with significant unmet need," said Rohan Palekar, president and CEO of Avanir. "We believe that ONZETRA Xsail—which delivers a fast-acting dry powder dosage of a leading migraine treatment in the first Breath Powered® intranasal delivery system—addresses one of the greatest challenges faced by migraine sufferers: obtaining rapid relief with a known side effect profile." Two key Avanir poster presentations that will highlight key pharmacokinetic and additional safety data for ONZETRA Xsail include: "Pharmacokinetic Modeling Study to Evaluate Two Intranasal Formulations of Sumatriptan for Nasal vs Gastrointestinal Tract Absorption" to be presented as a late-breaker by Dr. Laura Pope and Dr. Kenneth Schulman of Avanir Pharmaceuticals on Saturday, June 11 from 1:15-2:30 pm PT in the San Diego Ballroom (North Tower Lobby Level). Late Breaker Poster. "Characterizing the Most Common AEs Following Treatment with AVP-825: Exploring Abnormal Taste and Nasal Discomfort across Multiple Attacks in COMPASS Study" to be presented by Dr. James S. McGinley of Vector Psychometric Group on Friday, June 10 from 1:15-2:30 pm PT in the San Diego Ballroom (North Tower Lobby Level). Poster F13. Additional poster presentations for ONZETRA Xsail at AHS 2016 include: "Reduced Treatment-Emergent Nausea Using AVP-825 vs. Sumatriptan Tablets: A Comparative Effectiveness Study" to be presented by Dr. Kenneth Shulman of Avanir Pharmaceuticals on Friday, June 10 from 1:15-2:30 pm PT in the San Diego Ballroom (North Tower Lobby Level). Poster F15. "AVP-825 Reduces Nausea Faster Than Sumatriptan Tablets: A Comparative Effectiveness Study" to be presented by Dr. James McGinley of Vector Psychometric Group on Friday, June 10 from 1:15-2:30 pm PT in the San Diego Ballroom (North Tower Lobby Level). Poster F14. "Faster Migraine Relief Using AVP-825 Compared with Sumatriptan Tablet: Using a Latent Variable Perspective" to be presented by Dr. Richard Lipton of Albert Einstein College of Medicine on Friday, June 10 from 1:15-2:30 pm PT in the San Diego Ballroom (North Tower Lobby Level). Poster F16. "A Low Incidence of Atypical Sensations with AVP-825 (Breath Powered Intranasal Delivery System Containing 22 Mg Sumatriptan Powder) Migraine Therapy Across Multiple Phase 2/3 Clinical Trials" to be presented by Dr. Stewart Tepper of Geisel School of Medicine at Dartmouth on Friday, June 10 from 1:15-2:30 pm PT in the San Diego Ballroom (North Tower Lobby Level). Poster F11. Avanir Pharmaceuticals will be exhibiting at the meeting in Booth #207.